Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Long-term Pre-dialysis Extension in Europe and Asia Pacific (DIALOGUE 3)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02055482
Recruitment Status : Completed
First Posted : February 5, 2014
Last Update Posted : November 22, 2017
Sponsor:
Information provided by (Responsible Party):
Bayer

Brief Summary:

Anaemia is a condition in which blood has a lower than normal number of red blood cells. It can also occur if red blood cells do not contain enough haemoglobin, an oxygen carrying part of blood. Anaemia is common in patients with chronic kidney disease. Healthy kidneys produce a hormone called erythropoietin, which stimulates the bone marrow to produce the proper number of red blood cells needed to carry oxygen to vital organs. Chronic kidney disease is a general term that means that the kidneys are not functioning to their full potential. The study drug, BAY85-3934, is being evaluated as a drug to increase the body's ability to produce erythropoietin.

The purpose of this extension study is to find out if the study drug, a tablet taken orally, is safe and effective for the treatment of anaemia associated with chronic kidney disease.

The extension study will enroll up to 240 patients at multiple locations in Europe, Asia and Australia. Patients who participated in Studies 15141 or 15261 may be eligible to take part in the extension study. The study consists of the Haemoglobin (Hb) Stabilisation Phase and the Main Phase. The Hb Stabilisation Phase involves up to 10 study visits scheduled over 16 weeks. The Main Phase will last for at least 6 months and up to a maximum of 36 months, with visits every 4 weeks. During these scheduled visits patients will undergo a number of procedures to confirm efficacy and safety of the study drug, including measurement of heart rate and blood pressure, physical examination, Electrocardiogram and blood/urine sample collection for laboratory tests.

The study will be conducted at 5 hospitals in the UK. Bayer HealthCare AG is funding this research. This study will include subjects who either completed the treatment period in their respective Phase 2 parent study (i.e., Study 15141 or Study 15261) or experienced a stopping event in the fixed dose parent study (Study 15141). As Study 15141 is a double-blind study, subjects will be unblinded as per the Study 15141 protocol prior to entry into the extension study.


Condition or disease Intervention/treatment Phase
Anemia Renal Insufficiency, Chronic Drug: Molidustat (BAY85-3934) Biological: Darbepoetin Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 166 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Controlled, Parallel Group, Open-label, Multicenter Extension Study to Investigate Efficacy and Safety of Oral BAY85-3934 and Darbepoetin Alfa Comparator in the Long Term Treatment of Anemia in Pre-dialysis Subjects With Chronic Kidney Disease in Europe and Asia Pacific
Actual Study Start Date : June 24, 2014
Actual Primary Completion Date : November 15, 2016
Actual Study Completion Date : December 12, 2016

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Anemia

Arm Intervention/treatment
Experimental: BAY85-3934 Drug: Molidustat (BAY85-3934)
BAY85-3934 will be titrated at the scheduled dose control visits to maintain the Hb in the target range of 10.0 to 12.0 g/dL. Available doses include 15, 25, 50, 75, 100, and 150 mg/day OD. Treatment will be for minimum of 6 months to up to a maximum of 36 months.

Active Comparator: Darbepoetin Biological: Darbepoetin
Darbepoetin will be administered according to the local label and titrated at the scheduled dose by intravenous injection. Treatment will be for a minimum of 6 months to up to a maximum of 36 months.




Primary Outcome Measures :
  1. Change in local laboratory hemoglobin level from baseline [ Time Frame: Baseline up to 36 months ]
  2. Number of participants with serious adverse events (SAEs) and adjucated adverse events as a measure of safety and tolerability [ Time Frame: Up to 36 months ]
  3. Number of participants with liver function-related AEs including abnormal liver function tests and any hospitalization [ Time Frame: Up to 36 months ]

Secondary Outcome Measures :
  1. Time within hemoglobin target range (10.0 to 12.0 g/dL) [ Time Frame: Up to 36 months ]
  2. Duration of treatment exposure [ Time Frame: Up to 36 months ]
  3. Number of subjects requiring titration of dose [ Time Frame: Up to 36 months ]
  4. Change of reticulocyte count from baseline of this study [ Time Frame: Baseline up to 36 months ]
  5. Change of red blood cell count from baseline of this study [ Time Frame: Baseline up to 36 months ]
  6. Change of hematocrit from baseline of this study [ Time Frame: Baseline up to 36 months ]
  7. Change of central laboratory hemoglobin level from baseline of this study [ Time Frame: Baseline up to 36 months ]
  8. Responders in Hb levels [ Time Frame: Up to 36 months ]
  9. Number of subjects meeting specific Hb criteria [ Time Frame: Baseline up to 36 months ]
  10. Number of subjects with Hb values >13 g/dL or having excessive Hb increase [ Time Frame: Baseline up to 36 months ]
  11. Number of participants with non-serious adverse events [ Time Frame: Up to 36 months ]
  12. Change in heart rate (HR) [ Time Frame: Up to 36 months ]
  13. Change in blood pressure (BP) [ Time Frame: Up to 36 months ]
  14. Laboratory abnormalities [ Time Frame: Up to 36 months ]

Other Outcome Measures:
  1. Change of reticulocyte count from baseline of study 15141 or 15261 [ Time Frame: Baseline up to 36 months ]
  2. Change of red blood cell count from baseline of study 15141 or 15261 [ Time Frame: Baseline up to 36 months ]
  3. Change of hematocrit from baseline of study 15141 or 15261 [ Time Frame: Baseline up to 36 months ]
  4. Change of central laboratory hemoglobin level from baseline of study 15141 or 15261 [ Time Frame: Baseline up to 36 months ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Men who agree to use adequate contraception when sexually active or women without childbearing potential
  • Not on dialysis at study entry
  • Serum ferritin levels ≥ 100 μg/L and < 1000 μg/L or transferrin saturation ≥ 20%
  • Inclusion criteria for inclusion into the Hb Stabilization (HbS) Phase: Requires Hb stabilization (at 10.0 to 12..0g/dL for a minimum of 4 weeks) as follows: Received BAY 85-3934 and reached a stopping event in Study 15141 or received placebo and reached a stopping event in Study 15141 or completed 16 weeks of treatment with BAY 85-3934 in Study 15141or 15261 but had mean Hb during the evaluation period outside the target range of 10.0 to 12.0 g/dL, or Completed 16 weeks of treatment with placebo in Study 15141 and was re-assessed at 4 weeks after end of study as eligible for Study 15653 (this study)
  • Inclusion criteria for inclusion into the Main Phase: Mean Hb concentration of 10.0 to 12.0 g/dL who completed 16 weeks of treatment (BAY85-3934 arm) in Study 15141, or completed 16 weeks of treatment (BAY-3934 or darbepoetin arm)in study 15261 without a dose suspension lasting > 6 consecutive weeks, or mean Hb concentration of 10.0 to 12.0g/dL during the HbS phase of Study 15653 for a minimum of 4 weeks after visit 3.

Exclusion Criteria:

  • A scheduled kidney transplant or any other organ transplant within the next 6 months (being on a waiting list does not exclude the subject)
  • Red blood cell (RBC) containing transfusion within the 8 weeks before baseline
  • Phosphodiesterase type 5 (PDE5) inhibitor (e.g., sildenafil, vardenafil, tadalafil) or nitrates
  • Sustained, poorly controlled arterial hypertension or hypotension at baseline, defined as blood pressure ≥ 180/110 mmHg or systolic blood pressure < 95 mmHg, respectively
  • Severe rhythm or conduction disorders (e.g., heart rate [HR] < 50 or > 110 bpm, atrial flutter, prolonged QT > 500 msec, second or third degree atrioventricular [AV] block), if not reacted with a pace marker)
  • New York Heart Association Class III or IV congestive heart failure
  • Severe hepatic insufficiency (defined as alanine aminotransferase [ALT], aspartate aminotransferase [AST]>3x the upper limit of normal [ULN], total bilirubin > 2 mg/dL, or Child Pugh B or C) or active hepatitis, in the investigator's opinion
  • An ongoing serious adverse event (SAE) from Study 15141 or Study 15261 that is assessed as related to study drug

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02055482


Locations
Show Show 105 study locations
Sponsors and Collaborators
Bayer
Investigators
Layout table for investigator information
Study Director: Bayer Study Director Bayer

Additional Information:
Layout table for additonal information
Responsible Party: Bayer
ClinicalTrials.gov Identifier: NCT02055482    
Other Study ID Numbers: 15653
2013-001190-24 ( EudraCT Number )
First Posted: February 5, 2014    Key Record Dates
Last Update Posted: November 22, 2017
Last Verified: November 2017

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Bayer:
Anemia on CKD
Additional relevant MeSH terms:
Layout table for MeSH terms
Renal Insufficiency
Renal Insufficiency, Chronic
Anemia
Hematologic Diseases
Kidney Diseases
Urologic Diseases
Darbepoetin alfa
Hematinics